Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2109556 | 1.00 | CA1 (0.39) | CA1CA2ALDH1A1EPHX1ACHE | |
| SCHEMBL93215 | 1.00 | CA1 (0.39) | CA1CA2ALDH1A1EPHX1ACHE | |
| SCHEMBL2109539 | 1.00 | CA1 (0.39) | CA1CA2ALDH1A1EPHX1ACHE | |
| SCHEMBL9431 | 1.00 | — | — | |
| SCHEMBL302897 | 1.00 | CA1 (0.39) | CA1CA2ALDH1A1EPHX1ACHE | |
| SCHEMBL2110868 | 1.00 | CA1 (0.39) | CA1CA2ALDH1A1EPHX1ACHE | |
| SCHEMBL93454 | 1.00 | CA1 (0.39) | CA1CA2ALDH1A1EPHX1ACHE | |
| SCHEMBL2108202 | 1.00 | CA1 (0.39) | CA1CA2ALDH1A1EPHX1ACHE | |
| SCHEMBL2109113 | 1.00 | CA1 (0.39) | CA1CA2ALDH1A1EPHX1ACHE | |
| SCHEMBL93204 | 1.00 | CA1 (0.39) | CA1CA2ALDH1A1EPHX1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 628 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114014878-B | Conjugated alkenyl zinc reagent, preparation method and application thereof | 南开大学 | 2024-06-07 | — | — | CN | claimed |
| CN-116535439-B | Cyclopropane skeleton monophosphine ligand and palladium complex thereof, and preparation method and application thereof | 南开大学 | 2024-05-28 | — | — | CN | claimed |
| CN-116535439-A | Cyclopropane skeleton monophosphine ligand and palladium complex thereof, and preparation method and application thereof | 南开大学 | 2023-08-04 | — | — | CN | claimed |
| WO-2023142725-A1 | CYCLOPROPANE SKELETON MONOPHOSPHINE LIGAND AND PALLADIUM COMPLEX THEREOF AS WELL AS PREPARATION METHOD AND USE THEREOF | 南开大学 | 2023-08-03 | — | — | WO | claimed |
| CN-116003462-A | Silicon-based substituted chiral amine and preparation method and application thereof | 南开大学 | 2023-04-25 | — | — | CN | claimed |
| CN-115850328-A | Diphosphine ligand with cyclopropane skeleton and cobalt complex thereof, preparation method and application | 南开大学 | 2023-03-28 | — | — | CN | claimed |
| US-20220162219-A1 | Chiral Bisamino-Ether Compounds, And Method of Preparation and Use Thereof | UNIV JINAN (CN) | 2022-05-26 | — | — | US | claimed |
| CN-114249725-A | Preparation method and application of 2-imine-9-aryl substituted phenanthroline and iron complex thereof | 南开大学 | 2022-03-29 | — | — | CN | claimed |
| CN-114014878-A | Novel conjugated alkenyl zinc reagent, preparation method and application thereof | 南开大学 | 2022-02-08 | — | — | CN | claimed |
| CN-114014879-A | Optically active biaryl borane adduct and preparation method and application thereof | 南开大学 | 2022-02-08 | — | — | CN | claimed |
| US-20020006943-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. | 2002-01-17 | — | — | US | claimed |
| US-20010047006-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. | 2001-11-29 | — | — | US | claimed |
| WO-2001079167-A2 | ANTIPICORNAVIRAL COMPOUNDS AND COMPOSITIONS, THEIR PHARMACEUTICAL USES, AND MATERIALS FOR THEIR SYNTHESIS | AGOURON PHARMACEUTICALS, INC. (US) | 2001-10-25 | — | — | WO | claimed |
| WO-2001040189-A1 | ANTIPICORNAVIRAL COMPOUNDS AND COMPOSITIONS, THEIR PHARMACEUTICAL USES, AND MATERIALS FOR THEIR SYNTHESIS | AGOURON PHARMACEUTICALS, INC. (US) | 2001-06-07 | — | — | WO | claimed |
| US-4410522-A | BACTERICIDES | TOYAMA CHEMICAL CO., LTD. (JP) | 1983-10-18 | — | — | US | claimed |
| US-4269773-A | CEPHALOSPORINS | SHIONOGI & CO., LTD. (JP) | 1981-05-26 | — | — | US | claimed |
| US-4267340-A | BACTERICIDES; SYNTHESIS OF PENICILLINS AND CEPHALOSPORINS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-05-12 | — | — | US | claimed |
| US-4092474-A | Cephalosporins having a metaloxy group in 3-substituent | SHIONOGI & CO., LTD. (JA) | 1978-05-30 | — | — | US | claimed |
| US-4009159-A | PENICILLINS | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1977-02-22 | — | — | US | claimed |
| US-3993646-A | Process for the ring expansion of penicillins to cephalosporin compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1976-11-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162219-A1 | Chiral Bisamino-Ether Compounds, And Method of Preparation and Use Thereof | FHIT, BCAT1, BCAT2 | CA1 3841/4885CA2 4394/4885ALDH1A1 454/4885 |
| US-20010047006-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | RNASE1, SERPINB1, RNASEH1 | CA1 1893/4885CA2 2829/4885ALDH1A1 3180/4885 |
| US-20020006943-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | PRCP, RNPEP, SERPINB1 | CA1 2012/4885CA2 2829/4885ALDH1A1 3708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.